An Electrochemical Biosensor Based on a Myoglobin-specific Binding Peptide for Early Diagnosis of Acute Myocardial Infarction

Lee, Hyeong Yun; Choi, Ji Suk; Padmanaban, Guruprasath; Lee, Byungheon; Cho, Yong Woo

doi:10.2116/analsci.31.699

Cited by 42 publications

(21 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early diagnosis of myocardial infarction is an efficient method to decrease the mortality and morbidity of affected patients ( 22 , 23 ). At present, MRI is widely used for diagnosing myocardial infarction ( 14 , 15 ).…”

Section: Discussionmentioning

confidence: 99%

Combination of magnetic resonance imaging and targeted contrast agent for the diagnosis of myocardial infarction

Jiang-jun

Zhou

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

Myocardial infarction is one of the most common human cerebrovascular conditions and frequently leads to ischemic stroke. Evidence has indicated that magnetic resonance imaging (MRI) is a potential method for the diagnosis of patients with cardiovascular injury. However, the efficacy of MRI in diagnosing patients with myocardial infarction requires to be improved. In the present study, a novel nano-size contrast agent, a chitosan/Fe3O4-enclosed albumin (CFEA), was introduced that was used to quantify blood volume and permeability in the infarcted myocardium. A total of 68 patients with suspected myocardial infarction were recruited to analyze the efficacy of MRI combined with CFEA (MRI-CFEA). All patients received diagnosis by MRI and MRI-CFEA. It was revealed that MRI-CFEA provided a higher signal intensity than MRI in the same patients. It was demonstrated that the diagnostic efficacy of MRI-CFEA for patients with myocardial infarction was higher than that of MRI (P<0.05). By MRI-CFEA, 50/68 of cases with myocardial infarction were diagnosed, providing a significantly higher diagnostic rate compared with the 38/68 of cases diagnosed by contrast-enhanced MRI (P<0.01). MRI-CFEA successfully discriminated the infarcted regions based on a decreased fractional blood volume and increased permeability-surface (PS) area product in the infarcted myocardium. A pharmacodynamics analysis indicated that CFEA was eliminated within 24 h in all individuals. In conclusion, the present study provided a novel method to diagnose infarcted myocardium for patients with myocardial infarction, providing an imaging biomarker for the assessment of endothelial dysfunction in the clinic.

show abstract

Section: Discussionmentioning

confidence: 99%

Combination of magnetic resonance imaging and targeted contrast agent for the diagnosis of myocardial infarction

Jiang-jun

Zhou

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…The preparation of a peptide-based biosensor contains two main stages: receptor selection (via phage display) and functionalization of a transducer with synthetic peptides. This approach was used to develop sensors for detection of troponin I [51,65], myoglobin [69,70], alanine aminotransferase [66] or Norovirus coat protein [67,68]. An analogous scheme was used for detection of the Dengue virus type 2 marker (DENV2 NS1 protein) [53].…”

Section: Voltammetric and Impedimetricmentioning

confidence: 99%

Phage-Based Sensors in Medicine: A Review

2020

View full text Add to dashboard Cite

Bacteriophages are interesting entities on the border of biology and chemistry. In nature, they are bacteria parasites, while, after genetic manipulation, they gain new properties, e.g., selectively binding proteins. Owing to this, they may be applied as recognition elements in biosensors. Combining bacteriophages with different transducers can then result in the development of innovative sensor designs that may revolutionize bioanalytics and improve the quality of medical services. Therefore, here, we review the use of bacteriophages, or peptides from bacteriophages, as new sensing elements for the recognition of biomarkers and the construction of the highly effective diagnostics tools.

show abstract

“…New point-of-care devices have been proposed for the detection of Mb, used as a simple and reliable tool for the early diagnosis of AMI. 32,33 Regarding the association between survival and serum concentrations of various biomarkers, a cohort study conducted on 310 patients with idiopathic dilated cardiomyopathy (IDC) showed that from a panel of 3 biomarkers (cardiac troponin I, creatine kinase, and Mb) only cTnI proved to independently predict the all-cause death rates in IDC subjects. 34 …”

Section: Myoglobinmentioning

confidence: 99%

Recent Advances in Biomarker Discovery — from Serum to Imaging-based Biomarkers for a Complex Assessment of Heart Failure Patients

Chiotoroiu

Buicu

Neagu

et al. 2016

Journal of Interdisciplinary Medicine

View full text Add to dashboard Cite

Over the last years, a vast majority of serum biomarkers and imaging techniques have been used alone or combined in the diagnosis, management and prognosis of numerous pathologies. This review provides a brief insight into the novelties from the last 6 years (2010-2016) regarding serum and imaging markers in heart failure (HF). New information about natriuretic peptides (NPs), soluble ST2 (Sst2), growth differentiation factor 15 (GDF-15), myeloperoxidase (MPO), C-reactive protein (CRP), procalcitonin (PCT), troponins (Tns), myoglobin (Mb), galectin-3 (Gal-3), micro ribonucleic acids (microRNAs) and long non-coding ribonucleic acids (IncRNAs), copectin and cardiac magnetic resonance (CMR) measurements were summarized in this review in order to guide the practitioner.

show abstract

An Electrochemical Biosensor Based on a Myoglobin-specific Binding Peptide for Early Diagnosis of Acute Myocardial Infarction

Cited by 42 publications

References 35 publications

Combination of magnetic resonance imaging and targeted contrast agent for the diagnosis of myocardial infarction

Combination of magnetic resonance imaging and targeted contrast agent for the diagnosis of myocardial infarction

Phage-Based Sensors in Medicine: A Review

Recent Advances in Biomarker Discovery — from Serum to Imaging-based Biomarkers for a Complex Assessment of Heart Failure Patients

Contact Info

Product

Resources

About